Kesimpta (Ofatumumab) Dosage and Administration for Multiple Sclerosis in India

Understanding Kesimpta Dosage and Administration for Multiple Sclerosis in India

Multiple Sclerosis (MS) is a chronic, unpredictable disease that affects the central nervous system. In India, as in many parts of the world, managing MS involves a combination of medical treatments, lifestyle adjustments, and ongoing care. Kesimpta (ofatumumab) is a targeted therapy that has shown promise in treating certain forms of MS. This article provides a comprehensive guide to Kesimpta's dosage and administration, tailored for Indian patients and healthcare providers.

What is Kesimpta and How Does it Work?

Kesimpta is a biologic drug, meaning it is derived from living organisms. Its active ingredient is ofatumumab, which belongs to a class of medications called monoclonal antibodies. Unlike traditional chemotherapy, Kesimpta is specifically designed to target B cells, a type of white blood cell that plays a significant role in the immune system's attack on the central nervous system in MS. By depleting these B cells, Kesimpta helps to reduce inflammation and nerve damage associated with MS, thereby slowing disease progression and reducing the frequency of relapses.

Indications for Kesimpta Use

Kesimpta is approved for the treatment of adults with:

• Clinically Isolated Syndrome (CIS): This is often the first neurological episode that may indicate the presence of MS.
• Relapsing-Remitting Multiple Sclerosis (RRMS): Characterized by distinct attacks or relapses followed by periods of remission.
• Active Secondary Progressive Multiple Sclerosis (SPMS): A phase of MS where relapses may continue, and disability steadily worsens.

It is crucial to discuss with your neurologist whether Kesimpta is the right treatment option for your specific type and stage of MS.

Kesimpta Dosage Schedule: Loading Dose and Maintenance Dose

Kesimpta is administered via subcutaneous injection (under the skin). The dosage regimen is divided into two phases: a loading dose phase and a maintenance dose phase.

Loading Dose Phase:

The initial phase of treatment involves a higher frequency of injections to quickly establish therapeutic levels of the drug in the body. For most adults, the standard loading dose schedule is as follows:

• Week 1: 20 mg injection once weekly.
• Week 2: 20 mg injection once weekly.
• Week 3: 20 mg injection once weekly.

Following these three weekly injections, there is a 1-week break before transitioning to the maintenance dose.

Maintenance Dose Phase:

After completing the loading dose phase and the subsequent break, you will switch to a long-term maintenance dose. This involves less frequent injections to sustain the therapeutic effect of the medication.

• Starting from Week 5: 20 mg injection once per month.

This monthly injection schedule is typically continued as long as the treatment is deemed safe and effective by your doctor.

Kesimpta Forms and Strength

Kesimpta is available in a single strength of 20 mg of ofatumumab in 0.4 mL of liquid solution. It comes in two convenient, single-dose forms for self-administration:

• Sensoready Pen: A prefilled autoinjector pen designed for ease of use.
• Prefilled Syringe: A ready-to-use syringe containing the medication.

Your doctor will determine which form is most suitable for you and provide instructions on its use.

How to Administer Kesimpta Injections

Kesimpta is designed for self-injection, allowing patients to administer the medication at home. The injections are typically given into the subcutaneous tissue of the thigh or abdomen. If another person is administering the injection, the upper outer arm can also be used.

Preparation and Injection Technique:

1. Consult Your Doctor: Your first Kesimpta injection will likely be administered under the supervision of a healthcare professional. They will demonstrate the correct technique and answer any questions you may have.
2. Read Instructions: Carefully read the patient information leaflet and any diagrams or videos provided by the manufacturer regarding the use of the Sensoready pen or prefilled syringe.
3. Injection Sites: Choose an injection site on your thigh or abdomen. Avoid areas with bruises, cuts, redness, scaling, stretch marks, moles, or scars. Rotate injection sites with each dose to prevent skin irritation.
4. Hygiene: Ensure your hands are clean before preparing and administering the injection.
5. Administration: Follow the specific instructions for your chosen delivery device (Sensoready pen or prefilled syringe). This typically involves cleaning the injection site, preparing the device, and injecting the medication.
6. Disposal: Safely dispose of used needles and syringes in a designated sharps container.

Important Note: Always follow your doctor's specific instructions for administration. Do not inject into areas that are bruised, broken, red or discolored, scaly, tender, or marked with stretch marks, moles, or scars.

Storage of Kesimpta

Proper storage is essential to maintain the efficacy of Kesimpta:

• Refrigeration: Kesimpta should be stored in the refrigerator at a temperature between 2°C and 8°C (36°F to 46°F).
• Protection from Light: Keep the medication in its original carton until you are ready to use it to protect it from light exposure.
• Do Not Freeze: Never freeze Kesimpta. If it has been frozen, do not use it.

What to Do If You Miss a Dose

Missing a dose of Kesimpta can impact its effectiveness. If you miss a dose:

• Contact Your Doctor Immediately: Do not try to guess the correct dosage or timing. Call your doctor or healthcare provider as soon as you realize you have missed a dose. They will provide specific guidance on how to proceed, which may involve rescheduling the dose or adjusting the treatment plan.

Overdose and Emergency Situations

If you suspect you have injected too much Kesimpta:

• Call Your Doctor: Contact your doctor immediately for advice.
• Poison Control: You can also call India's national poison control helpline or your local emergency services.
• Severe Symptoms: If you experience severe symptoms, call emergency services (like 108 in India) or go to the nearest emergency room immediately.

Long-Term Treatment with Kesimpta

Kesimpta is generally considered a long-term treatment for MS. If you and your doctor find that the medication is safe and effective for managing your condition, you will likely continue using it for an extended period. Regular monitoring and follow-up appointments with your neurologist are crucial to assess treatment effectiveness and manage any potential side effects.

Accessibility Features

For individuals who may have difficulty reading prescription labels, several options are available:

• Inform Your Doctor/Pharmacist: Let your doctor or pharmacist know if you have trouble reading your medication labels.
• Accessible Labels: Some pharmacies can provide medication labels with features like scannable QR codes that convert text to audio.
• Pharmacy Assistance: Your doctor or pharmacist can help you find pharmacies that offer these accessibility services.

Additionally, using medication reminder apps or setting alarms on your phone can help ensure you adhere to your injection schedule.

When to Consult a Doctor

It is essential to maintain open communication with your healthcare provider. Consult your doctor if you experience any of the following:

• New or worsening symptoms of MS.
• Signs of infection (fever, chills, sore throat, cough, etc.).
• Any unusual or concerning side effects.
• Questions about your dosage or administration.
• If you are pregnant, planning to become pregnant, or breastfeeding.

Conclusion

Kesimpta offers a valuable treatment option for adults with certain types of MS in India. Understanding the correct dosage, administration, and storage is vital for maximizing its benefits and ensuring safety. Always adhere to your doctor's prescribed regimen and consult them for any concerns or questions regarding your treatment. Regular medical follow-ups are key to managing MS effectively and maintaining a good quality of life.

Frequently Asked Questions (FAQ)

Q1: What is the primary goal of Kesimpta treatment?

A1: The primary goal of Kesimpta treatment is to reduce the frequency of relapses and slow the progression of disability in adults with certain types of Multiple Sclerosis by targeting and depleting specific immune cells (B cells) that contribute to nerve damage.

Q2: Can Kesimpta be used for children with MS?

A2: Kesimpta is currently approved for use in adults only. Its safety and efficacy in children have not been established.

Q3: How long does the loading dose phase last?

A3: The loading dose phase consists of three weekly injections of 20 mg each, followed by a 1-week break before starting the monthly maintenance dose.

Q4: What are the common injection sites for Kesimpta?

A4: Common injection sites are the thigh or abdomen. If administered by another person, the upper outer arm can also be used. It's important to rotate sites and avoid areas with skin issues.

Q5: Is Kesimpta a cure for Multiple Sclerosis?

A5: Kesimpta is not a cure for Multiple Sclerosis. It is a disease-modifying therapy that helps to manage the condition, reduce relapses, and slow disease progression.